Financial Performance - The company's operating revenue for 2022 is expected to be ¥190,930,536.43, representing a 13.54% increase compared to the previous year [3]. - The net profit attributable to shareholders is expected to be ¥40,177,056.22, a decrease of 17.01% year-on-year [5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be ¥37,842,737.52, down 14.40% from the previous year [3]. - Basic earnings per share are expected to decline by 23.29% to ¥0.56 [3]. Assets and Equity - Total assets at the end of the reporting period are expected to be ¥636,793,119.52, an increase of 171.24% from the beginning of the period [4]. - Shareholders' equity attributable to the company is expected to reach ¥554,789,463.14, up 239.16% from the beginning of the period [4]. - The total share capital is expected to increase by 37.43% to ¥91,515,941.00 [4]. Factors Affecting Performance - The decline in net profit is primarily due to the impact of recurring COVID-19, changes in product sales structure, and increased R&D expenses [7]. - The company has increased its R&D investment and issued shares to unspecified qualified investors, contributing to the increase in total assets and equity [7]. Cautionary Notes - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks [8].
新芝生物(430685) - 2022 Q4 - 年度业绩